最新！山东罗欣法人、总经理刘振腾卸任

Core Viewpoint - The recent personnel changes at Luoxin Pharmaceutical, particularly the replacement of Liu Zhenteng with Chen Yu as the legal representative and general manager of Shandong Luoxin, signify a strategic shift aimed at clarifying internal roles and enhancing operational efficiency [1][3][4]. Group 1: Personnel Changes - Liu Zhenteng, the son of the founder, has stepped down from his roles at Shandong Luoxin but remains as chairman of Luoxin Pharmaceutical [1][3]. - Chen Yu, a veteran with extensive technical and production experience, has taken over as general manager, which is expected to improve the company's production and operational quality [3][4]. - The company has undergone at least eight personnel changes in 2025, indicating a trend towards appointing executives with financial and auditing backgrounds to strengthen capital operations and financial structure [5][6][19]. Group 2: Financial Performance - Shandong Luoxin's revenue has significantly declined from 64.81 billion to 22.92 billion from 2021 to 2024, with net profits showing losses of -10.34 billion, -5.37 billion, and -6.32 billion during the same period [4][16]. - In the first half of 2025, Shandong Luoxin managed to turn a profit of 21.93 million, indicating a potential recovery [4][16]. - Luoxin Pharmaceutical has also faced declining revenues and profits, with net losses of -14.48 billion, -6.39 billion, and -7.68 billion from 2022 to 2024, raising concerns about the risk of being classified as a "ST" (special treatment) company [7][19]. Group 3: Strategic Initiatives - The company is actively pursuing asset optimization strategies, including the sale of subsidiaries to improve resource allocation and liquidity [9][21]. - Luoxin Pharmaceutical plans to raise up to 842.4 million through a targeted A-share issuance to fund innovative drug development and facility upgrades [10][22]. - The company has received a significant capital injection of 130 million from a local government fund, which is expected to provide essential support for its operations and strategic initiatives [10][22].